More in-depth understanding of the biology of the CD137-CD137L co-stimulation system opens an opportunity to identify new prognostic biomarkers and the design of novel therapeutic approaches for advancing the management of SLE. This evidence concerns the gene TNFSF9 and systemic lupus erythematosus.